(73 intermediate revisions by the same user not shown) | |||
Line 56: | Line 56: | ||
#abstract{ | #abstract{ | ||
− | background-color: rgba( | + | background-color: rgba(147,251,152,0.9); |
position: fixed; | position: fixed; | ||
− | margin: | + | margin: 1.25em 20em 0 20em; |
height: 90%; | height: 90%; | ||
z-index:-1; | z-index:-1; | ||
+ | font-family:'Comic Sans MS','Arial Black'; | ||
display: none; | display: none; | ||
+ | border:solid 1px white; | ||
+ | |||
} | } | ||
#scroll_to_bottom{ | #scroll_to_bottom{ | ||
− | |||
position: fixed; | position: fixed; | ||
text-align: center; | text-align: center; | ||
color: #ffffff; | color: #ffffff; | ||
font-weight: bold; | font-weight: bold; | ||
− | + | bottom: 10%; | |
+ | left: 40%; | ||
} | } | ||
− | @media screen and (max-width: | + | @media screen and (max-width: 1170px) { |
.menu{ | .menu{ | ||
display: none; | display: none; | ||
− | |||
} | } | ||
Line 84: | Line 86: | ||
} | } | ||
+ | @media screen and (max-width: 980px){ | ||
+ | #ClickBack{ | ||
+ | display: none; | ||
+ | } | ||
+ | #abstract{ | ||
+ | background-color: rgba(147,251,152,0.9); | ||
+ | position: fixed; | ||
+ | margin: 45% auto 0 auto; | ||
+ | min-height: 40em; | ||
+ | height:auto; | ||
+ | z-index:-1; | ||
+ | font-family:'Comic Sans MS','Arial Black'; | ||
+ | border:solid 1px white; | ||
+ | display: block; | ||
+ | overflow:hidden; | ||
+ | } | ||
+ | #scroll_to_bottom{ | ||
+ | display: none; | ||
+ | } | ||
+ | body{ | ||
+ | background-color: white; | ||
+ | } | ||
+ | .menu{ | ||
+ | display: none; | ||
+ | } | ||
− | @media screen and (min-width: | + | .container { |
+ | display: block; | ||
+ | } | ||
+ | } | ||
+ | @media screen and (min-width: 1170px) { | ||
.menu{ | .menu{ | ||
Line 96: | Line 127: | ||
} | } | ||
− | + | ||
− | + | #abstract #guanjian {margin-left:7em;font-family:'Comic Sans MS','Arial Black';font-size:16px;} | |
− | font- | + | p{ |
+ | margin-left: 5em; | ||
+ | margin-right: 5em; | ||
+ | font-family:'Comic Sans MS','Arial Black'; | ||
} | } | ||
− | h1 | + | h1{ |
− | margin-left: | + | margin-left: 4.5em; |
− | margin-right: | + | margin-right: 5em; |
− | margin-top: | + | margin-top: 3.5em; |
+ | font-family:'Comic Sans MS','Arial Black'; | ||
} | } | ||
#ClickBack{ | #ClickBack{ | ||
text-align: center; | text-align: center; | ||
position: fixed; | position: fixed; | ||
− | bottom: | + | bottom: 3em; |
− | right: | + | right: 18em; |
display:none; | display:none; | ||
+ | font-family:'Comic Sans MS','Arial Black'; | ||
} | } | ||
#ClickBack img{ | #ClickBack img{ | ||
− | width: | + | width: 6em; |
} | } | ||
+ | |||
</style> | </style> | ||
Line 137: | Line 174: | ||
$("#abstract").slideToggle(); | $("#abstract").slideToggle(); | ||
$("#ClickBack").slideToggle(); | $("#ClickBack").slideToggle(); | ||
+ | $("#scroll_to_bottom").slideToggle(); | ||
}); | }); | ||
Line 142: | Line 180: | ||
$("#abstract").fadeOut("slow"); | $("#abstract").fadeOut("slow"); | ||
$("#ClickBack").fadeOut("slow"); | $("#ClickBack").fadeOut("slow"); | ||
+ | $("#scroll_to_bottom").fadeIn("slow"); | ||
}); | }); | ||
}); | }); | ||
+ | |||
</script> | </script> | ||
</head> | </head> | ||
− | <body | + | <body> |
− | + | ||
− | + | ||
+ | <!-- small screen menu --> | ||
+ | |||
<div class="container" > | <div class="container" > | ||
<ul id="gn-menu" class="gn-menu-main" > | <ul id="gn-menu" class="gn-menu-main" > | ||
Line 170: | Line 210: | ||
</li> | </li> | ||
<li> | <li> | ||
− | <a href="https://2016.igem.org/Team:NAU-CHINA/ | + | <a href="https://2016.igem.org/Team:NAU-CHINA/Part_Collection"> PARTS</a> |
</li> | </li> | ||
+ | |||
<li><a href="https://2016.igem.org/Team:NAU-CHINA/Safety"> SAFETY</a></li> | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Safety"> SAFETY</a></li> | ||
− | <li><a href="https://2016.igem.org/Team:NAU-CHINA/ | + | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Attributions"> ATTRIBUTION</a></li> |
<li> | <li> | ||
<a href="https://2016.igem.org/Team:NAU-CHINA/Human_Practices"> HP</a> | <a href="https://2016.igem.org/Team:NAU-CHINA/Human_Practices"> HP</a> | ||
Line 188: | Line 229: | ||
− | + | <nav> | |
<!-- big screen menu--> | <!-- big screen menu--> | ||
− | |||
<div class="nav" id="main" role="main"> | <div class="nav" id="main" role="main"> | ||
<ul class="menu"> | <ul class="menu"> | ||
Line 197: | Line 237: | ||
<ul class="submenu"> | <ul class="submenu"> | ||
<li><a href="https://2016.igem.org/Team:NAU-CHINA/Participator">Participator</a></li> | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Participator">Participator</a></li> | ||
− | <li><a href="https://2016.igem.org/Team:NAU-CHINA/ | + | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Collaborations">Collaboration</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
Line 203: | Line 243: | ||
<ul class="submenu"> | <ul class="submenu"> | ||
<li><a href="https://2016.igem.org/Team:NAU-CHINA/Description">Description</a></li> | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Description">Description</a></li> | ||
− | <li><a href="https://2016.igem.org/Team:NAU-CHINA/ | + | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Design">Applied Design</a></li> |
<li><a href="https://2016.igem.org/Team:NAU-CHINA/Experiment">Experiment</a></li> | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Experiment">Experiment</a></li> | ||
− | <li><a href="https://2016.igem.org/Team:NAU-CHINA/ | + | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Proof">Proof of Concept</a></li> |
<li><a href="https://2016.igem.org/Team:NAU-CHINA/Demonstrate">Demonstrate </a></li> | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Demonstrate">Demonstrate </a></li> | ||
<li><a href="https://2016.igem.org/Team:NAU-CHINA/Model">Model </a></li> | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Model">Model </a></li> | ||
− | |||
<li><a href="https://2016.igem.org/Team:NAU-CHINA/Notebook">Notebook </a></li> | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Notebook">Notebook </a></li> | ||
</ul> | </ul> | ||
Line 214: | Line 253: | ||
<li><a>PARTS</a> | <li><a>PARTS</a> | ||
<ul class="submenu"> | <ul class="submenu"> | ||
− | <li><a href="https://2016.igem.org/Team:NAU-CHINA/ | + | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Part_List">Part List</a></li> |
− | <li><a href="https://2016.igem.org/Team:NAU-CHINA/ | + | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Basic_Part">Basic Part</a></li> |
− | + | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Composite_Part">Composite Part</a></li> | |
+ | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Part_Collection">Collection</a></li> | ||
</ul> | </ul> | ||
</li> | </li> | ||
<li><a href="https://2016.igem.org/Team:NAU-CHINA/Safety">SAFETY</a></li> | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Safety">SAFETY</a></li> | ||
− | <li><a href="https://2016.igem.org/Team:NAU-CHINA/ | + | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Attributions">ATTRIBUTION</a></li> |
<li><a>HUMAN PRACTICE</a> | <li><a>HUMAN PRACTICE</a> | ||
<ul class="submenu"> | <ul class="submenu"> | ||
<li><a href="https://2016.igem.org/Team:NAU-CHINA/Human_Practices">Human Practices</a></li> | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Human_Practices">Human Practices</a></li> | ||
− | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Silver">Silver</a></li> | + | <li><a href="https://2016.igem.org/Team:NAU-CHINA/HP/Silver">Silver</a></li> |
− | <li><a href="https://2016.igem.org/Team:NAU-CHINA/Gold">Gold</a></li> | + | <li><a href="https://2016.igem.org/Team:NAU-CHINA/HP/Gold">Gold</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
Line 233: | Line 273: | ||
</nav> | </nav> | ||
<img src="https://static.igem.org/mediawiki/2016/e/e8/NAU_CHINA_2016WIKI_HOME.jpeg" onload="ChangeImg(this)" style="z-index:-60;position:absolute;left:0;top:0px"><!--backgroundimg--> | <img src="https://static.igem.org/mediawiki/2016/e/e8/NAU_CHINA_2016WIKI_HOME.jpeg" onload="ChangeImg(this)" style="z-index:-60;position:absolute;left:0;top:0px"><!--backgroundimg--> | ||
− | + | <div> | |
<div name="abstract" id="abstract"> | <div name="abstract" id="abstract"> | ||
− | <h1>The Birth of Healer & A Story of Us</h1> | + | <br><br> |
− | <p>Several ideas were created and several ideas were denied. Our eyes were blocked by <b style="font-weight: bold;color: | + | <h1 style="font-family:'Comic Sans MS','Arial Black';font-size:20px;">The Birth of Healer & A Story of Us</h1> |
− | <ul>Key words: | + | <p style="font-family:'Comic Sans MS','Arial Black';font-size:17px;">Several ideas were created and several ideas were denied. Our eyes were blocked by <b style="font-weight: bold;color:blue;">3-phenoxybenzoate acid(3-PBA)</b>, the main intermediate product of pyrethroids. But what is 3-PBA and what are pyrethroids? Why we need to degrade 3-PBA thoroughly and how to degrade it through employing microbial biodegradation techniques? Once our Healer (the engineered bacteria) were born, how to put it into practice? From knowing to deep knowing, our efforts made it real.</p><br> |
+ | <ul id="guanjian">Key words: | ||
<li>Cause <span>(what is 3-PBA and what are pyrethroids? Why we need to degrade 3-PBA thoroughly?)</span></li> | <li>Cause <span>(what is 3-PBA and what are pyrethroids? Why we need to degrade 3-PBA thoroughly?)</span></li> | ||
<li>Method <span>(How to degrade it through employing microbial biodegradation techniques?)</span></li> | <li>Method <span>(How to degrade it through employing microbial biodegradation techniques?)</span></li> | ||
<li>Extention <span>(How to put it into practice?)</span></li> | <li>Extention <span>(How to put it into practice?)</span></li> | ||
</ul> | </ul> | ||
− | + | <br><br> | |
</div> | </div> | ||
− | + | <br style="clear:both;"></div> | |
+ | <div id="ClickBack"> | ||
<img src="https://static.igem.org/mediawiki/2016/e/e9/NAU_CHINA_2016_ClickToBack.gif"> | <img src="https://static.igem.org/mediawiki/2016/e/e9/NAU_CHINA_2016_ClickToBack.gif"> | ||
<p>Click Me Back</p> | <p>Click Me Back</p> | ||
− | </div> | + | </div> |
<div id="scroll_to_bottom"> | <div id="scroll_to_bottom"> |
Latest revision as of 18:17, 19 October 2016
The Birth of Healer & A Story of Us
Several ideas were created and several ideas were denied. Our eyes were blocked by 3-phenoxybenzoate acid(3-PBA), the main intermediate product of pyrethroids. But what is 3-PBA and what are pyrethroids? Why we need to degrade 3-PBA thoroughly and how to degrade it through employing microbial biodegradation techniques? Once our Healer (the engineered bacteria) were born, how to put it into practice? From knowing to deep knowing, our efforts made it real.
- Key words:
- Cause (what is 3-PBA and what are pyrethroids? Why we need to degrade 3-PBA thoroughly?)
- Method (How to degrade it through employing microbial biodegradation techniques?)
- Extention (How to put it into practice?)
Click Me Back
Click here to see more